Struggling With Great Stock Picks? Discover StockInvest.us Top Gems!
NASDAQ:ECYT
Delisted

Endocyte Fund Price (Quote)

$23.99
+0 (+0%)
At Close: Jan 18, 2019

Range Low Price High Price Comment
30 days $23.97 $24.00 Friday, 18th Jan 2019 ECYT stock ended at $23.99. During the day the stock fluctuated 0% from a day low at $23.99 to a day high of $23.99.
90 days $23.37 $24.00
52 weeks $2.81 $24.00

Historical Endocyte prices

Date Open High Low Close Volume
Nov 05, 2018 $23.50 $23.89 $23.50 $23.78 1 971 439
Nov 02, 2018 $23.63 $23.67 $23.50 $23.51 2 470 912
Nov 01, 2018 $23.59 $23.65 $23.43 $23.63 2 648 671
Oct 31, 2018 $23.66 $23.74 $23.58 $23.65 2 756 959
Oct 30, 2018 $23.50 $23.73 $23.50 $23.57 3 655 596
Oct 29, 2018 $23.65 $23.71 $23.41 $23.47 2 618 164
Oct 26, 2018 $23.59 $23.73 $23.50 $23.65 2 672 377
Oct 25, 2018 $23.44 $23.70 $23.43 $23.70 5 428 515
Oct 24, 2018 $23.47 $23.56 $23.37 $23.39 5 278 036
Oct 23, 2018 $23.43 $23.60 $23.42 $23.54 4 898 884
Oct 22, 2018 $23.44 $23.59 $23.41 $23.52 5 488 816
Oct 19, 2018 $23.39 $23.50 $23.30 $23.48 14 514 878
Oct 18, 2018 $23.37 $23.54 $23.33 $23.40 46 744 619
Oct 17, 2018 $15.97 $16.03 $15.30 $15.56 523 257
Oct 16, 2018 $15.32 $16.19 $15.32 $15.95 936 964
Oct 15, 2018 $15.39 $15.49 $14.94 $15.24 619 624
Oct 12, 2018 $15.33 $15.63 $15.05 $15.39 830 920
Oct 11, 2018 $14.77 $15.35 $14.50 $15.03 1 145 114
Oct 10, 2018 $15.00 $15.52 $14.68 $14.93 1 003 878
Oct 09, 2018 $15.54 $16.12 $15.35 $15.50 812 186
Oct 08, 2018 $15.68 $16.08 $15.16 $15.64 1 028 258
Oct 05, 2018 $15.70 $16.07 $15.12 $15.93 1 548 499
Oct 04, 2018 $16.68 $16.89 $15.26 $15.62 1 901 250
Oct 03, 2018 $17.19 $17.42 $16.35 $16.96 1 371 266
Oct 02, 2018 $17.77 $17.85 $17.10 $17.22 1 008 667
Click to get the best stock tips daily for free!

About Endocyte

Endocyte, Inc., a biopharmaceutical company, develops targeted therapies for the treatment of cancer and inflammatory diseases in the United States. The company uses its technology to create novel small molecule drug conjugates (SMDCs) and companion imaging agents. It is developing Vintafolide, a SMDC that is in Phase IIb clinical trials to treat non-small cell lung cancer; EC1456, which is in Phase I dose escalation trial for the treatment of ad... ECYT Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT